Molecular Pathology, Diagnostics, and Therapeutics of Lung Disease
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 23
Special Issue Editor
Interests: Ras mutations; Ras targeting inhibitor; resistance to Ras inhibition; potential combination therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Respiratory diseases are extremely diverse and include infectious diseases, bronchial asthma, chronic obstructive pulmonary disease, lung cancer, interstitial lung disease, and more. Each condition presents unique and complex challenges. In recent years, diagnosis and treatment in these areas have steadily evolved and are poised for continued development. By gathering studies to share and discuss latest findings in this Special Issue, we hope to spark a movement in research and development, leading to new diagnostic and treatment methods and bringing about major changes.
The keyword for this Special Issue is "exchange". For each field to evolve, the true nature of a disease must be identified. To uncover this, various ideas must be developed, and hypotheses must be formulated and proven. New trends can be created by engaging in this Special Issue. Hypothesis and proof are the essence of medical research. Let us gather, discuss, and consider the mystery of the respiratory system.
We believe that the results will not only contribute to the development of this Special Issue but will also contribute to appropriate medical treatment and the provision of safe and secure medical care.
We hope to make this Special Issue a success together with all of you. We look forward to your submissions.
Dr. Toshimitsu Yamaoka
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pulmonary diseases
- diagnostics
- therapeutics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
